Matinas BioPharma Holdings, Inc. (MTNB)
0.8557
-0.07
(-7.69%)
USD |
NYAM |
Nov 17, 16:00
0.8134
-0.04
(-4.94%)
After-Hours: 20:00
Matinas BioPharma Holdings EPS Diluted (Quarterly) : -9.348 for Sept. 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -9.348 |
| June 30, 2026 | -3.105 |
| March 31, 2026 | -4.498 |
| December 31, 2025 | -4.477 |
| September 30, 2025 | -5.933 |
| June 30, 2025 | -15.47 |
| March 31, 2025 | -4.883 |
| December 31, 2024 | -24.87 |
| September 30, 2024 | -12.73 |
| June 30, 2024 | -17.20 |
| March 31, 2024 | -20.09 |
| December 31, 2023 | -18.34 |
| September 30, 2023 | -20.90 |
| June 30, 2023 | -20.92 |
| March 31, 2023 | -19.03 |
| December 31, 2022 | -12.57 |
| September 30, 2022 | -18.88 |
| June 30, 2022 | -20.48 |
| March 31, 2022 | -20.69 |
| December 31, 2021 | -23.24 |
| September 30, 2021 | -23.83 |
| June 30, 2021 | -18.19 |
| March 31, 2021 | -19.01 |
| December 31, 2020 | -24.68 |
| September 30, 2020 | -21.40 |
| Date | Value |
|---|---|
| June 30, 2020 | -21.97 |
| March 31, 2020 | -20.42 |
| December 31, 2019 | -26.76 |
| September 30, 2019 | -21.82 |
| June 30, 2019 | -18.91 |
| March 31, 2019 | -27.58 |
| December 31, 2018 | -26.16 |
| September 30, 2018 | -25.80 |
| June 30, 2018 | -30.00 |
| March 31, 2018 | -34.13 |
| December 31, 2017 | -29.14 |
| September 30, 2017 | -28.84 |
| June 30, 2017 | -30.00 |
| March 31, 2017 | -187.50 |
| December 31, 2016 | -24.40 |
| September 30, 2016 | -82.50 |
| June 30, 2016 | -22.50 |
| March 31, 2016 | -30.00 |
| December 31, 2015 | -26.31 |
| September 30, 2015 | -30.00 |
| June 30, 2015 | -30.00 |
| March 31, 2015 | -52.50 |
| December 31, 2014 | -70.70 |
| September 30, 2014 | -60.00 |
| June 30, 2014 | -60.00 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 0.305 |
| Alnylam Pharmaceuticals, Inc. | 15.72 |
| Anika Therapeutics, Inc. | -0.0232 |
| Savara, Inc. | -0.1691 |
| Arrowhead Pharmaceuticals, Inc. | -3.029 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -6.514M |
| Total Expenses (Quarterly) | 6.514M |
| Enterprise Value | -1.040M |
| Earnings Yield | -2.50K% |
| Normalized Earnings Yield | -2574.56 |